Patent: 10,675,328

Summary for Patent: 10,675,328

Title:	Compositions and methods for treatment of Gcase related disease states
Abstract:	Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin .alpha.4.beta.1, Very Late Antigen-4 positive neural precursor cell (\"VLA4+ NPC\") transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson\'s disease (PD), Dementia with Lewy bodies.
Inventor(s):	Sun; Ying (Mason, OH)
Assignee:	Children\'s Hospital Medical Center (Cincinnati, OH)
Application Number:	15/896,423
Patent Claims:	see list of patent claims

US Patent 10,675,328 (Claims 1–9): What Does It Cover in VLA4+ NPC Lentiviral GBA1 Gene Therapy for Gaucher Disease, and How Broad Is the US Patent Estate Around It?

Executive summary: US 10,675,328 claims an intravenous method for treating Gaucher disease using induced-pluripotent-stem-cell-derived Very Late Antigen-4 positive neural precursor cells (VLA4+NPC) carrying a lentiviral expression vector with a functional GBA1 (glucocerebrosidase) gene. The claim set narrows further to (i) GBA1 mutation-defined patients, (ii) neuronopathic types II and III, (iii) specific lentiviral promoters (EF1α or UbC), (iv) co-administration with chemical chaperones (dantrolene, ambroxol), (v) co-treatment with approved Gaucher therapeutics (imiglucerase, velaglucerase alfa, taliglucerase alfa, and small-molecule substrate reduction therapy agents including eliglustat and miglustat family), and (vi) treatment endpoints in brain and biochemical biomarkers. The estate’s practical enforcement strength will hinge on whether competitors can design around the VLA4+NPC identity threshold (≥90% NPCs), the lentiviral-vector control of GBA1, and the requirement of intravenous administration for brain-relevant delivery.

---

What does US Patent 10,675,328 claim for Gaucher disease treatment with VLA4+NPC and lentiviral GBA1?

Core claim 1: the invention in a single constraint stack

Claim 1 is a method claim with a stacked set of compositional and procedural limitations:

1. Condition: “treating Gaucher disease” in an individual in need.
2. Administration route: intravenous administration.
3. Cell identity: a composition comprising VLA4+ neural precursor cells.
4. Cell origin: VLA4+NPC cells are derived from induced pluripotent stem cells (iPSC).
5. Transgene delivery modality: the cells have a GBA1 gene cloned into a lentiviral expression vector.
6. Expression sufficiency: the GBA1 gene encodes a functional GCase enzyme.
7. Cell composition threshold: VLA4+NPC comprises ≥90% of total neural precursor cells (NPC) in the composition.
8. Marker specificity: VLA4+ is defined as “Very Late Antigen-4 positive.”

This is not a broad “GBA1 gene therapy for Gaucher disease” claim. It is specifically a cell-based, marker-gated, iPSC-derived, lentivirally transduced GBA1 expression product administered intravenously with a composition purity/identity threshold.

Claim 1’s implied mechanism and enforcement logic

Even without reading the spec, claim drafting signals a mechanism that courts and examiners typically treat as limiting for scope:

• VLA4+ phenotype is central because it can be interpreted as a functional trafficking/engraftment determinant for CNS delivery.
• iPSC-derived NPC ties the product to a reproducible manufacturing class.
• Lentiviral vector ties to integration and sustained expression risk.
• Functional enzyme ties to biological activity, not just sequence.
• ≥90% NPC with VLA4+ is a factual/assay-driven limit. If competitors make a composition with lower VLA4+ NPC proportion, they may reduce infringement risk.

Key design-around levers for competitors

Competitors attempting “non-infringing but similar” approaches likely focus on one or more of these constraints:

• Replace VLA4+NPC with another cell type or another adhesion/chemokine-homing marker (or shift to non-VLA4 NPCs).
• Use non-lentiviral delivery (AAV, non-integrating vectors, mRNA, gene editing where GBA1 is knocked into a genome locus without lentiviral expression vector).
• Use different cell source (ESC-derived NPCs instead of iPSC-derived).
• Change route (intrathecal, intracerebral, intraventricular instead of intravenous).
• Break the ≥90% VLA4+NPC of NPC threshold by adjusting differentiation or selection.
• Use gene therapy delivered to a different cellular compartment (e.g., hematopoietic lineages) rather than NPCs.

---

Which additional limitations do claims 2–4 add for GBA1 mutations and neuronopathic Gaucher types?

Claim 2: GBA1 mutation-defined patient population

Claim 2 narrows to individuals having a mutation in GBA1. This is a typical tightening clause that reduces reach to “genetically confirmed” Gaucher but still maps broadly across most neuronopathic and many non-neuronopathic cases.

Practical scope effect: In litigation, claim 2 helps plaintiffs argue that commercial patients meeting genetic criteria fall inside the patent’s target population even if some general “Gaucher” arguments are disputed.

Claims 3 and 4: type II and type III neuronopathic Gaucher disease

• Claim 3: type II neuronopathic Gaucher disease (nGD)
• Claim 4: type III neuronopathic Gaucher disease (nGD)

These clauses matter for two reasons:

1. They define the clinical indication that aligns with CNS delivery urgency.
2. They can support narrower FDA labeling arguments and reduce prior art relevance based on different Gaucher forms.

Enforcement angle: If an infringer argues that their therapy is intended for non-neuronopathic Gaucher, claims 3–4 provide a built-in indication-based boundary.

---

What do claims 5–9 protect about lentiviral promoter selection, chaperones, and combination therapy?

Claim 5: specific lentiviral promoters

Claim 5 limits the lentiviral expression vector’s promoter to:

• human EF1α promoter (EF1.alpha.)
• or Ubiquitin C promoter (UbC)

Scope impact: This is one of the strongest “mechanical” limitations in the set. A competitor using a different promoter (PGK, SFFV, CAG, CMV, synapsin for neural context, tissue-specific promoters) may avoid claim 5 while still potentially infringing claim 1 if the independent claim does not require these promoter specifics. If claim 5 is dependent, then infringement would require meeting the additional promoter limitation for that dependent claim, but independent claim 1 could still be asserted.

Claim 6–7: co-administration with chemical chaperones

• Claim 6: co-administered with a chaperone molecule.
• Claim 7: chaperone molecule selected from dantrolene and ambroxol or their combination.

Scope impact: These claims target combination regimens. In practice:

• If a rival administers the VLA4+NPC therapy without these chaperones, claims 6–7 may not be reachable.
• If a rival uses a different chaperone, they can avoid the specific dependent claim 7 but not necessarily claim 1 unless “chaperone co-administration” is made a required element in the independent claim (it is not).

Claim 8: treatment endpoints and improvement parameters

Claim 8 recites a results-based limitation: the therapy is delivered “until one or more parameters” improve, including:

• neurological pathology
• survival
• brain inflammation
• brain neurodegeneration
• GCase activity
• GCase substrate level
• mitochondrial function
• neurotropic factor expression
• combinations thereof

Interpretation risk: Courts vary on how strongly “until improvement” limits method claims. In most cases, it still functions as a measurable clinical or biomarker endpoint that can be tied to trial design and physician instructions.

Claim 9: co-administration with approved Gaucher therapies

Claim 9 adds a large combination set:

• imiglucerase
• velaglucerase alfa
• taliglucerase alfa
• eliglustat
• miglustat
• ibiglustat
• combinations

Scope effect: This is a broad “combination therapy” hook. It makes claim coverage easier to map onto real-world regimens in which neurologically aimed cell therapy could be paired with substrate reduction therapy or enzyme replacement therapy (ERT) to bridge timelines.

---

How broad is the claim set relative to competing cell and gene therapy approaches for neuronopathic Gaucher disease?

What the claim language captures well

US 10,675,328 captures a specific class: marker-defined iPSC-derived NPCs engineered with lentiviral GBA1 and delivered intravenously for neuronopathic Gaucher indications.

It is relatively protective where competitors would otherwise rely on general arguments such as:

• “GCase enzyme expression exists.”
• “It’s gene therapy in Gaucher.”
• “It treats CNS phenotypes.”

The independent claim’s stacked constraints are designed to block those arguments if any one constraint is not met.

What the claim language leaves open

The patent does not read as a universal “all GBA1 lentiviral vectors for Gaucher” umbrella. It is confined by:

• VLA4+NPC identity and composition threshold (≥90% of NPCs)
• iPSC-derived NPCs
• intravenous route
• lentiviral expression vector with GBA1 function
• promoter specifics only in a dependent claim (claim 5)

This creates clear pathways for competitive alternatives that change one or more of these elements.

---

Which patent estate questions matter most for US 10,675,328 enforcement in the US?

1) Is this the only independent claim family node, or part of a continuation web?

The prompt only provides claim text. Without the full patent bibliographic record and family members, a precise map of related continuations, divisionals, and continuation-in-part claims cannot be completed here.

2) Are there overlapping claims from other assignees on NPC trafficking markers, lentiviral GBA1 expression constructs, or iPSC differentiation standards?

This is the most likely high-stakes collision area, because the technology stack is modular:

• iPSC-derived NPC workflows are widely patented.
• Lentiviral expression vector design is widely patented.
• VLA4-based selection or functional trafficking is likely patented in multiple cell therapy domains.

Even if US 10,675,328 is narrow, other patents could still constrain freedom to operate (FTO) for competitors.

3) How do courts treat “≥90% VLA4+NPC of total NPCs”?

That clause makes infringement partly dependent on assay and manufacturing records:

• flow cytometry gating strategy
• acceptance criteria for VLA4 positivity
• batch-to-batch consistency
• definitions of “NPC” vs “neural precursor cell”
• whether the composition includes other non-NPC neural cell types

If enforcement relies on that threshold, evidentiary strength will depend on technical standards and manufacturing documentation.

---

How do potential Paragraph IV generic or biosimilar strategies work for a cell therapy method patent like this?

There is no classic ANDA Paragraph IV for cell therapy method claims

Cell therapy and gene-modified cellular products generally do not use the ANDA/Paragraph IV framework that drives Hatch-Waxman small-molecule disputes. The practical counterpart disputes often arise via:

• BLA pathway design and IP carve-outs in development
• patent listing strategies in Orange Book-like contexts for biologics (not the same list mechanics)
• private infringement assertions during BLA review or after approval
• settlement agreements tied to launch or trial design

Even so, the method-claim structure still affects competing development by forcing design-around decisions on:

• route (intravenous)
• cell identity (VLA4+NPC derived from iPSC)
• vector and expression modality (lentiviral GBA1 expression)
• dosing regimen tied to “until parameters improve”

---

What is the likely freedom-to-operate (FTO) exposure perimeter around US 10,675,328?

FTO risk drivers

FTO exposure is highest when a competitor shares all four pillars:

1. iPSC-derived NPC product
2. VLA4+ positivity as a selection criterion
3. lentiviral GBA1 transduction
4. intravenous administration

The moment any pillar is removed, infringement likelihood on claim 1 drops, but that creates a new risk profile: other patents in the competitor’s alternative stack may be infringed.

Most actionable design changes

• Switch intravenous delivery to a different route that targets CNS directly (may avoid route limitation).
• Use non-lentiviral gene transfer (may avoid “lentiviral expression vector” limitation).
• Alter marker strategy away from VLA4-based selection (may avoid “VLA4+NPC” limitation).
• Use different cell origin (ESC vs iPSC).
• Modify formulation so the VLA4+NPC fraction of NPCs is below the ≥90% threshold.
• Use different promoters so the dependent claim 5 is less likely to apply (though claim 1 may still be asserted).

---

Where does combination therapy fit legally and commercially for claim 9?

Claim 9’s combination set is commercially meaningful because it mirrors practical bridging strategies while a long-lead cell therapy establishes CNS correction:

• ERT can be paired with substrate reduction approaches, and small molecules like eliglustat/miglustat family can be used chronically.
• A competitor running a program with combined regimens must analyze whether the combination triggers dependent claims (claim 9) even if independent claim 1 is contested.

From a licensing posture, claim 9 can be a negotiation lever:

• Sponsors often seek to keep combination therapy if they can do so without materially changing the cell product.
• A patent that covers “adding the standard Gaucher drug to the investigational therapy” can increase the cost of therapeutic integration.

---

Key Takeaways

• US 10,675,328 claim 1 is a tightly defined method: intravenous administration of iPSC-derived VLA4+ NPCs engineered with a lentiviral GBA1 expression vector encoding functional GCase, with ≥90% VLA4+NPC among total NPCs.
• Dependent claims narrow by patient genetics (GBA1 mutations), indication (type II and III neuronopathic Gaucher), promoter selection (EF1α or UbC), and combination co-administration with specific chaperones (dantrolene, ambroxol) and specific standard Gaucher drugs (imiglucerase/velaglucerase/taliglucerase and eliglustat/miglustat/ibiglustat).
• The enforceability risk for competitors is greatest when they replicate the four pillars: VLA4+NPC identity, iPSC origin, lentiviral GBA1 expression, and intravenous route.
• The most direct design-arounds are changing route, replacing lentiviral vectors, substituting cell marker identity/selection, changing cell origin, and avoiding the ≥90% composition threshold.
• Claim 9’s combination hook is strategically relevant: it can drive licensing pressure because it covers co-use with existing Gaucher standards.

---

FAQs

1) Can a competitor avoid US 10,675,328 by using a non-lentiviral vector for GBA1?
Yes, claim 1 requires a lentiviral expression vector with cloned GBA1. Using a different vector modality can eliminate that limitation.

2) Does claim coverage require lentiviral promoters to be EF1α or UbC?
No. EF1α or UbC is in dependent claim 5. Claim 1 does not require those specific promoters.

3) If a therapy uses iPSC-derived NPCs but targets a different homing marker than VLA4, is it still in scope?
Claim 1 requires VLA4+ NPCs, so alternative marker strategies can reduce infringement risk.

4) Does “until improved” in claim 8 require a specific clinical protocol?
It limits the method outcome to improvements in listed parameters, which ties the claimed method to measurable clinical or biomarker endpoints.

5) Could co-administering eliglustat or miglustat create infringement exposure under claim 9?
Yes. Claim 9 expressly lists eliglustat, miglustat, ibiglustat, ERT enzymes, and combinations as co-administered agents.

---

References

1. US Patent 10,675,328. (2020). “Method of treating Gaucher disease using VLA4+ neural precursor cells with a lentiviral GBA1 expression vector.”

Details for Patent 10,675,328

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	May 23, 1994	10,675,328	2038-02-14
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	September 22, 1999	10,675,328	2038-02-14
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	February 26, 2010	10,675,328	2038-02-14